NR3C2 and hydrops fetalis: Similarly, prescriptions of disease-modifying HF drugs (i.e., beta-blockers, renin–angiotensin system inhibitors, mineralocorticoid receptor antagonists, and SGLT2is) were more frequent in patients with HFrEF than in those with the other HF EF phenotypes.